News

Filter

Current filters:

Pricing

76 to 85 of 97511 results

OncoGenex’ Ph III custirsen trial cleared to continue

16-01-2015

Canada’s OncoGenex Pharmaceuticals says that the AFFINITY trial is continuing as planned based upon…

custirsenOncoGenex PharmaceuticalsOncologyPharmaceuticalResearch

Akorn files ANDA for generic Durezol

16-01-2015

US generic drugmaker Akorn has confirmed that it has filed an Abbreviated New Drug Application (ANDA)…

AkornAlconDurezolGenericsNovartisOphthalmicsPatentsRegulationUSA

WuXi acquires NextCODE Health in $65 million cash deal

WuXi acquires NextCODE Health in $65 million cash deal

16-01-2015

Shanghai-headquartered pharmatech company WuXi has acquired NextCODE Health, a genomic analysis and bioinformatics…

ChinaMergers & AcquisitionsNextCODE HealthPharmaceuticalWuXi PharmaTech

Cellectis links with Ohio State University on multiple myeloma technology

16-01-2015

France-based genome engineering specialist Cellectis has entered into an exclusive license agreement…

BiotechnologyCD123CD38CellectisCS1LicensingOncologyResearch

Health management program from Practice Fusion and Merck encourages vaccine uptake

Health management program from Practice Fusion and Merck encourages vaccine uptake

16-01-2015

Cloud-based electronic record service Practice Fusion and pharma giant Merck & Co have collaborated on…

MedicineMerck & CoPractice FusionResearchVaccines

Roche continues spending spree, with acquisition of French biotech firm Trophos

Roche continues spending spree, with acquisition of French biotech firm Trophos

16-01-2015

Continuing its recent spate of deal-making, Swiss pharma giant Roche has agreed to acquire Trophos, a…

BiotechnologyMergers & AcquisitionsolesoximeRare diseasesRocheSwitzerlandTrophos

EC approves AbbVie’s Viekirax + Exviera for hepatitis C

EC approves AbbVie’s Viekirax + Exviera for hepatitis C

16-01-2015

The European Commission has granted marketing authorizations for US drugmaker AbbVie’s all-oral, short-course,…

AbbVieAnti-viralsEuropeExvieraPharmaceuticalRegulationViekirax

Amgen trials show no differences in quality of life between the FOLFOX regimens with or without Vectibix

Amgen trials show no differences in quality of life between the FOLFOX regimens with or without Vectibix

16-01-2015

USA-based Amgen, the world’s leading independent biotech firm, says that Phase II and Phase III studies…

AmgenBiotechnologyOncologyResearchVectibix

76 to 85 of 97511 results

Back to top